Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review

Journal of Affective Disorders

Volumn 227, Issue , 2018, Pages 406-415

  Lee, Yena ^a,b   Rosenblat, Joshua D ^b,c   Lee, JungGoo ^d,e   Carmona, Nicole E ^b   Subramaniapillai, Mehala ^b   Shekotikhina, Margarita ^b,f   Mansur, Rodrigo B ^b,c   Brietzke, Elisa ^b,g   Lee, Jae Hon ^h   Ho, Roger C ⁱ   Yim, Samantha J ^b   McIntyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Inje University   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f UNIVERSITY OF OTTAWA   (Canada)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h Korea University College of Medicine   (South Korea)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antidepressant; Cost modelling; Depression; Disability; Functional outcomes; Functioning; Quality of life; Work

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESVENLAFAXINE; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; FLUOXETINE; MILNACIPRAN; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; VORTIOXETINE;

ABSENTEEISM; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; PRODUCTIVITY; RATING SCALE; RETURN TO WORK; REVIEW; SYSTEMATIC REVIEW; WORK DISABILITY; WORKPLACE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISABILITY; DOUBLE BLIND PROCEDURE; ECONOMICS; JOB PERFORMANCE; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WORK PERFORMANCE; WORKPLACE;

EID: 85037662377     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.11.003     Document Type: Review

References (68)

1. Aikens, J.E., Kroenke, K., Nease, D.E. Jr, Klinkman, M.S., Sen, A., Trajectories of improvement for six depression-related outcomes. Gen. Hosp. Psychiatry 30 (2008), 26–31.
2. Asnis, G.M., Bose, A., Gommoll, C.P., Chen, C., Greenberg, W.M., Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 74 (2013), 242–248.
3. Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W.M., Liebowitz, M., Khan, A., Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J. Psychiatry Neurosci. 39 (2014), 40–49.
4. Beck, A., Crain, A.L., Solberg, L.I., Unützer, J., Glasgow, R.E., Maciosek, M.V., Whitebird, R., Severity of depression and magnitude of productivity loss. Ann. Fam. Med. 9 (2011), 305–311.
5. Beck, A., Crain, L.A., Solberg, L.I., Unützer, J., Maciosek, M.V., Whitebird, R.R., Rossom, R.C., The effect of depression treatment on work productivity. Am. J. Manag. Care 20 (2014), e294–301.
6. Boulenger, J.-P., Loft, H., Olsen, C.K., Efficacy and safety of vortioxetine (lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int. Clin. Psychopharmacol. 29 (2014), 138–149.
7. Boyer, P., Danion, J.M., Bisserbe, J.C., Hotton, J.M., Troy, S., Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in france. Pharmacoeconomics 13 (1998), 157–169.
8. de Vries, G., Koeter, M.W.J., Nieuwenhuijsen, K., Hees, H.L., Schene, A.H., Predictors of impaired work functioning in employees with major depression in remission. J. Affect. Disord. 185 (2015), 180–187.
9. Detke, M.J., Wiltse, C.G., Mallinckrodt, C.H., McNamara, R.K., Demitrack, M.A., Bitter, I., Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 14 (2004), 457–470.
10. Dunlop, B.W., Reddy, S., Yang, L., Lubaczewski, S., Focht, K., Guico-Pabia, C.J., Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J. Clin. Psychopharmacol. 31 (2011), 569–576.
11. Endicott, J., Nee, J., Endicott work productivity scale (EWPS): a new measure to assess treatment effects. Psychopharmacol. Bull. 33 (1997), 13–16.
12. F.M.D.T.M.P. for Behavioral Health, Florida Best Practice Psychotherapeutic Medication Guidelines for Adults, Technical Report, Florida Medicaid Drug Therapy Management Program for Behavioral Health, 2015.
13. Frazer, A., Blier, P., Neuroscience-Based, A., nomenclature (NbN) for psychotropic agents. Int. J. Neuropsychopharmacol., 19, 2016.
14. Gaynor, P.J., Gopal, M., Zheng, W., Martinez, J.M., Robinson, M.J., Hann, D., Marangell, L.B., Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Curr. Med. Res. Opin. 27 (2011), 1859–1867.
15. Gaynor, P.J., Gopal, M., Zheng, W., Martinez, J.M., Robinson, M.J., Marangell, L.B., A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr. Med. Res. Opin. 27 (2011), 1849–1858.
16. Gelenberg, A.J., Freeman, M.P., Markowitz, J.C., Rosenbaum, J.F., Thase, M.E., Trivedi, M.H., Van Rhoads, R.S., 2010. Treatment of Patients With Major Depressive Disorder, Technical Report, American Psychiatric Association.
17. Geraedts, A.S., Fokkema, M., Kleiboer, A.M., Smit, F., Wiezer, N.W., Majo, M.C., van Mechelen, W., Cuijpers, P., Penninx, B.W.J.H., The longitudinal prediction of costs due to health care uptake and productivity losses in a cohort of employees with and without depression or anxiety. J. Occup. Environ. Med. 56 (2014), 794–801.
18. Global Burden of Disease Study 2013 Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 386 (2013), 743–800.
19. Goldstein, B.I., Carnethon, M.R., Matthews, K.A., McIntyre, R.S., Miller, G.E., Raghuveer, G., Stoney, C.M., Wasiak, H., McCrindle, B.W., American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young, Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American heart association. Circulation 132 (2015), 965–986.
20. Greden, J.F., Workplace depression: personalize, partner, or pay the price. Am. J. Psychiatry 170 (2013), 578–581.
21. Greenberg, P.E., Fournier, A.-A., Sisitsky, T., Pike, C.T., Kessler, R.C., The economic burden of adults with major depressive disorder in the united states (2005 and 2010). J. Clin. Psychiatry 76 (2015), 155–162.
22. Hewett, K., Gee, M.D., Krishen, A., Wunderlich, H.-P., Le Clus, A., Evoniuk, G., Modell, J.G., Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J. Psychopharmacol. 24 (2010), 1209–1216.
23. Jette, A.M., Davies, A.R., Cleary, P.D., Calkins, D.R., Rubenstein, L.V., Fink, A., Kosecoff, J., Young, R.T., Brook, R.H., Delbanco, T.L., The functional status questionnaire: reliability and validity when used in primary care. J. Gen. Intern. Med. 1 (1986), 143–149.
24. Katona, C., Hansen, T., Olsen, C.K., A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 27 (2012), 215–223.
25. Kennedy, S.H., Avedisova, A., Belaïdi, C., Picarel-Blanchot, F., de Bodinat, C., Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur. Neuropsychopharmacol. 26 (2016), 378–389.
26. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., Wang, P.S., National Comorbidity Survey Replication, The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 289 (2003), 3095–3105.
27. Lagerveld, S.E., Bültmann, U., Franche, R.L., van Dijk, F.J.H., Vlasveld, M.C., van der Feltz-Cornelis, C.M., Bruinvels, D.J., Huijs, J.J.J.M., Blonk, R.W.B., van der Klink, J.J.L., Nieuwenhuijsen, K., Factors associated with work participation and work functioning in depressed workers: a systematic review. J. Occup. Rehabil. 20 (2010), 275–292.
28. Lee, Y., Smofsky, A., Nykoliation, P., Allain, S., Lewis-Daly, L., Schwartz, J., et al. Cognitive Impairment Mediates Workplace Impairment in Persons with Type 2 Diabetes Mellitus: Results From the Motivaction Study. Can J Diabetes., 2017, 10.1016/j.jcjd.2017.06.013.
29. Lerner, D., Amick, B.C. 3rd, Rogers, W.H., Malspeis, S., Bungay, K., Cynn, D., The work limitations questionnaire. Med. Care 39 (2001), 72–85.
30. Linde, K., Kriston, L., Rücker, G., Jamil, S., Schumann, I., Meissner, K., Sigterman, K., Schneider, A., Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann. Fam. Med. 13 (2015), 69–79.
31. Mahableshwarkar, A.R., Zajecka, J., Jacobson, W., Chen, Y., Keefe, R.S.E., A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40 (2015), 2025–2037.
32. Mahableshwarkar, A.R., Jacobsen, P.L., Serenko, M., Chen, Y., Trivedi, M.H., A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J. Clin. Psychiatry 76 (2015), 583–591.
33. McIntyre, R.S., Lee, Y., Cognition in major depressive disorder: a systemically important functional index (SIFI). Curr. Opin. Psychiatry 29 (2016), 48–55.
34. McIntyre, R.S., Liauw, S., Taylor, V.H., Depression in the workforce: the intermediary effect of medical comorbidity. J. Affect. Disord. 128:Suppl 1 (2011), S29–S36.
35. McIntyre, R.S., Lophaven, S., Olsen, C.K., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 17 (2014), 1557–1567.
36. McIntyre, R.S., Soczynska, J.Z., Woldeyohannes, H.O., Alsuwaidan, M.T., Cha, D.S., Carvalho, A.F., Jerrell, J.M., Dale, R.M., Gallaugher, L.A., Muzina, D.J., Kennedy, S.H., The impact of cognitive impairment on perceived workforce performance: results from the international mood disorders collaborative project. Compr. Psychiatry 56 (2015), 279–282.
37. McIntyre, R.S., Florea, I., Tonnoir, B., Loft, H., Lam, R.W., Christensen, M.C., Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J. Clin. Psychiatry 78 (2017), 115–121.
38. Montgomery, S.A., Mansuy, L., Ruth, A., Bose, A., Li, H., Li, D., Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J. Clin. Psychiatry 74 (2013), 363–369.
39. Montgomery, S.A., Nielsen, R.Z., Poulsen, L.H., Häggström, L., A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum. Psychopharmacol. 29 (2014), 470–482.
40. Mundt, J.C., Clarke, G.N., Burroughs, D., Brenneman, D.O., Griest, J.H., Effectiveness of antidepressant pharmacotherapy: the impact of medication compliance and patient education. Depression Anxiety 13 (2001), 1–10.
41. Nakonezny, P.A., Carmody, T.J., Morris, D.W., Kurian, B.T., Trivedi, M.H., Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. Int. Clin. Psychopharmacol. 25 (2010), 328–333.
42. Nicholson, S., Sweeney, M., Whiteley, M.S.J., Harnett, M.A.J., Is there a business case for reducing employees' antidepressant prescription drug cost sharing?. J. Health Prod., 2012.
43. Nieuwenhuijsen, K., Franche, R.-L., van Dijk, F.J.H., Work functioning measurement: tools for occupational mental health research. J. Occup. Environ. Med. 52 (2010), 778–790.
44. Nieuwenhuijsen, K., Faber, B., Verbeek, J.H., Neumeyer-Gromen, A., Hees, H.L., Verhoeven, A.C., van der Feltz-Cornelis, C.M., Bültmann, U., 2014. Interventions to improve return to work in depressed people, Cochrane Database Syst. Rev. CD006237.
45. Paunio, T., Korhonen, T., Hublin, C., Partinen, M., Koskenvuo, K., Koskenvuo, M., Kaprio, J., Poor sleep predicts symptoms of depression and disability retirement due to depression. J. Affect. Disord. 172 (2015), 381–389.
46. Reilly, M.C., Zbrozek, A.S., Dukes, E.M., The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4 (1993), 353–365.
47. Rizvi, S.J., Cyriac, A., Grima, E., Tan, M., Lin, P., Gallaugher, L.A., McIntyre, R.S., Kennedy, S.H., Depression and employment status in primary and tertiary care settings. Can. J. Psychiatry 60 (2015), 14–22.
48. Rock, P.L., Roiser, J.P., Riedel, W.J., Blackwell, A.D., Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 44 (2014), 2029–2040.
49. Rosenblat, J.D., Kakar, R., McIntyre, R.S., The cognitive effects of antidepressants in major depressive disorder: a systematic review and Meta-Analysis of randomized clinical trials. Int. J. Neuropsychopharmacol., 19, 2015.
50. Rossom, R.C., Solberg, L.I., Vazquez-Benitez, G., Whitebird, R.R., Crain, A.L., Beck, A., Unützer, J., Predictors of poor response to depression treatment in primary care. Psychiatr. Serv. 67 (2016), 1362–1367.
51. Rothschild, A.J., Raskin, J., Wang, C.-N., Marangell, L.B., Fava, M., The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr. Psychiatry 55 (2014), 1–10.
52. S.A. Office of Applied Studies, M. H. S. A. (samhsa), The NSDUH Report: Depression among adults employed full-time, by occupational category, Technical Report, Substance Abuse and Mental Health Services Administration (SAMHSA), 2017.
53. Sambunaris, A., Bose, A., Gommoll, C.P., Chen, C., Greenberg, W.M., Sheehan, D.V., A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J. Clin. Psychopharmacol. 34 (2014), 47–56.
54. Sheehan, K.H., Sheehan, D.V., Assessing treatment effects in clinical trials with the discan metric of the sheehan disability scale. Int. Clin. Psychopharmacol. 23 (2008), 70–83.
55. Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A., The measurement of disability. Int. Clin. Psychopharmacol. 11:Suppl 3 (1996), S89–S95.
56. Sheehan, D.V., Nakagome, K., Asami, Y., Pappadopulos, E.A., Boucher, M., Restoring function in major depressive disorder: a systematic review. J. Affect. Disord. 215 (2017), 299–313.
57. Soczynska, J.K., Ravindran, L.N., Styra, R., McIntyre, R.S., Cyriac, A., Manierka, M.S., Kennedy, S.H., The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res. 220 (2014), 245–250.
58. Stewart, W.F., Ricci, J.A., Chee, E., Hahn, S.R., Morganstein, D., Cost of lost productive work time among US workers with depression. JAMA 289 (2003), 3135–3144.
59. Teismann, T., von Brachel, R., Hanning, S., Grillenberger, M., Hebermehl, L., Hornstein, I., Willutzki, U., A randomized controlled trial on the effectiveness of a rumination-focused group treatment for residual depression. Psychother. Res. 24 (2014), 80–90.
60. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., STAR*D Study Team, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
61. Trivedi, M.H., Morris, D.W., Wisniewski, S.R., Lesser, I., Nierenberg, A.A., Daly, E., Kurian, B.T., Gaynes, B.N., Balasubramani, G.K., Rush, A.J., Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am. J. Psychiatry 170 (2013), 633–641.
62. Vigo, D., Thornicroft, G., Atun, R., Estimating the true global burden of mental illness. Lancet Psychiatry 3 (2016), 171–178.
63. Vinckier, F., Gourion, D., Mouchabac, S., Anhedonia predicts poor psychosocial functioning: results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur. Psychiatry 44 (2017), 1–8.
64. Wang, P.S., Simon, G.E., Avorn, J., Azocar, F., Ludman, E.J., McCulloch, J., Petukhova, M.Z., Kessler, R.C., Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA 298 (2007), 1401–1411.
65. Wang, G., Gislum, M., Filippov, G., Montgomery, S., Comparison of vortioxetine versus venlafaxine XR in adults in asia with major depressive disorder: a randomized, double-blind study. Curr. Med. Res. Opin. 31 (2015), 785–794.
66. Watanabe, N., Omori, I.M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R., Furukawa, T.A., 2011. Mirtazapine versus other antidepressive agents for depression, Cochrane Database Syst. Rev. CD006528.
67. Watkins, E.R., Mullan, E., Wingrove, J., Rimes, K., Steiner, H., Bathurst, N., Eastman, R., Scott, J., Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomised controlled trial. Br. J. Psychiatry 199 (2011), 317–322.
68. World Health Organization, Depression and Other Common Mental Disorders: Global Health Estimates. 2017, World Health Organization, Geneva, Switzerland (Technical report).